1. The FDA-approved drug Alectinib compromises SARS-CoV-2 nucleocapsid phosphorylation and inhibits viral infection in vitro
- Author
-
Yaron, Tomer M., primary, Heaton, Brook E., additional, Levy, Tyler M., additional, Johnson, Jared L., additional, Jordan, Tristan X., additional, Cohen, Benjamin M., additional, Kerelsky, Alexander, additional, Lin, Ting-Yu, additional, Liberatore, Katarina M., additional, Bulaon, Danielle K., additional, Kastenhuber, Edward R., additional, Mercadante, Marisa N., additional, Shobana-Ganesh, Kripa, additional, He, Long, additional, Schwartz, Robert E., additional, Chen, Shuibing, additional, Weinstein, Harel, additional, Elemento, Olivier, additional, Piskounova, Elena, additional, Nilsson-Payant, Benjamin E., additional, Lee, Gina, additional, Trimarco, Joseph D., additional, Burke, Kaitlyn N., additional, Hamele, Cait E., additional, Chaparian, Ryan R., additional, Harding, Alfred T., additional, Tata, Aleksandra, additional, Zhu, Xinyu, additional, Tata, Purushothama Rao, additional, Smith, Clare M., additional, Possemato, Anthony P., additional, Tkachev, Sasha L., additional, Hornbeck, Peter V., additional, Beausoleil, Sean A., additional, Anand, Shankara K., additional, Aguet, François, additional, Getz, Gad, additional, Davidson, Andrew D., additional, Heesom, Kate, additional, Kavanagh-Williamson, Maia, additional, Matthews, David, additional, tenOever, Benjamin R., additional, Cantley, Lewis C., additional, Blenis, John, additional, and Heaton, Nicholas S., additional
- Published
- 2020
- Full Text
- View/download PDF